A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
Clinical trial NCT06671054 · RECRUITING
Trial details
- NCT number
- NCT06671054
- Sponsor
- SynAct Pharma Aps
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-01
- Primary completion
- 2025-12-01
- Enrollment
- 240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.